Luciano Saso

Rome, 00185, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 347 publications

Correction: Tber et al. Pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5-amines as Potential Cytotoxic Agents Against Human Neuroblastoma. Pharmaceuticals 2021, 14, 750.

Correction: Tber et al. Pyrido[2',1':2,3]imidazo[4,5-c]isoquinolin-5-amines as Potential Cytotoxic Agents Against Human Neuroblastoma. Pharmaceuticals 2021, 14, 750.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: August 06, 2026

Engineering nanoparticles for macrophage reprogramming in chronic inflammatory diseases: current advances, challenges, and future perspectives.

Engineering nanoparticles for macrophage reprogramming in chronic inflammatory diseases: current advances, challenges, and future perspectives.

Journal: Frontiers in bioengineering and biotechnology

Published: June 04, 2026

Recent advancements in NRF2-regulated ferroptosis modulation for targeted cancer therapy.

Recent advancements in NRF2-regulated ferroptosis modulation for targeted cancer therapy.

Journal: Molecular biology reports

Published: June 01, 2026

Metal carcinogens and cancer: integrating genetic and epigenetic perspectives.

Metal carcinogens and cancer: integrating genetic and epigenetic perspectives.

Journal: Frontiers in oncology

Published: May 31, 2026

Toll/IL-1 receptor domain-containing adaptor protein plays a crucial role in macrophage-mediated hepatic stellate cell activation in alcoholic liver disease.

Toll/IL-1 receptor domain-containing adaptor protein plays a crucial role in macrophage-mediated hepatic stellate cell activation in alcoholic liver disease.

Journal: Frontiers in cell and developmental biology

Published: May 16, 2026

Ribosomal proteins, miRNAs, and extracellular vesicles in myelodysplastic syndromes: molecular regulation and biomarker potential.

Ribosomal proteins, miRNAs, and extracellular vesicles in myelodysplastic syndromes: molecular regulation and biomarker potential.

Journal: Frontiers in oncology

Published: April 23, 2026

NRF2 as a guardian of health: from an ancient survival pathway to a modern therapeutic target.

NRF2 as a guardian of health: from an ancient survival pathway to a modern therapeutic target.

Journal: Redox biology

Published: March 11, 2026

Targeting MLKL-Driven Necroptosis: A Therapeutic Target in Inflammation and Host Defense.

Targeting MLKL-Driven Necroptosis: A Therapeutic Target in Inflammation and Host Defense.

Journal: Biomolecules

Published: February 04, 2026

Nrf2 in obesity: Mechanisms, models, and bioactive modulators.

Nrf2 in obesity: Mechanisms, models, and bioactive modulators.

Journal: Obesity research & clinical practice

Published: December 01, 2025

Nrf2 Modulation by Natural Compounds in Aging, Neurodegeneration, and Neuropathic Pain.

Nrf2 Modulation by Natural Compounds in Aging, Neurodegeneration, and Neuropathic Pain.

Journal: Pharmaceutics

Published: November 27, 2025

Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications.

Dimethyl fumarate as a versatile therapeutic agent: molecular mechanisms and potential clinical applications.

Journal: Molecular biology reports

Published: November 07, 2025

Biophysical insights into the molecular mechanisms of beta amyloid aggregation and its toxic effects in Alzheimer's disease.

Biophysical insights into the molecular mechanisms of beta amyloid aggregation and its toxic effects in Alzheimer's disease.

Journal: Frontiers in molecular biosciences

Published: September 13, 2025

Showing 1-12 of 347

Last Updated: 09/26/2026